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Abstract
Research on malaria vaccines is currently directed primarily towards the development of vaccines
that prevent clinical malaria. Malaria elimination, now being considered seriously in some
epidemiological situations, requires a different vaccine strategy, since success will depend on killing
all parasites in the community in order to stop transmission completely.
The feature of the life-cycles of human malarias that presents the greatest challenge to an
elimination programme is the persistence of parasites as asymptomatic infections. These are an
important source from which transmission to mosquitoes can occur. Consequently, an elimination
strategy requires a community-based approach covering all individuals and not just those who are
susceptible to clinical malaria.
The progress that has been made in development of candidate malaria vaccines is reviewed. It is
unlikely that many of these will have the efficacy required for complete elimination of parasites,
though they may have an important role to play as part of future integrated control programmes.
Vaccines for elimination must have a high level of efficacy in order to stop transmission to
mosquitoes. This might be achieved with some pre-erythrocytic stage candidate vaccines or by
targeting the sexual stages directly with transmission-blocking vaccines. An expanded malaria
vaccine programme with such objectives is now a priority.
Background
Development of a malaria vaccine has been difficult.
Greatly expanded investment in malaria vaccine research
and development in recent years has resulted in the iden-
tification of a substantial number of vaccine candidates
that are now in clinical trials or in the late stages of pre-
clinical development. Now the malaria vaccine commu-
nity is faced with a new challenge. Do the vaccine
development plans developed several years ago, when the
main target of malaria vaccine development was reduc-
tion in the burden of clinical malaria, fit with the new and
ambitious aim of achieving malaria elimination. Here the
current situation with respect to malaria control, the par-
ticular challenges elimination strategies present, and the
progress being made in vaccine development are consid-
ered. An assessment is made of what vaccines are needed
and how they could be used most effectively as part of a
malaria elimination programme.
The much quoted figures for malaria deaths and clinical
cases – around 1 million deaths and 300–500 million
clinical cases per annum, are still the best estimates avail-
able. The majority of these deaths are due to Plasmodium
falciparum malaria and occur in sub-Saharan Africa [1].
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The importance of Plasmodium vivax infection, in particu-
lar in South-East Asia, and the severity of some infections
caused by this malaria parasite have been underestimated
but are now receiving more attention [2].
There are, however, encouraging recent reports that show
that a very significant improvement in the malaria situa-
tion is possible using existing control tools. Effective
malaria control in high transmission areas seemed a
remote possibility, even just a few years ago, but, with the
substantial increase in political commitment and finan-
cial investment in control measures over the past 5–6
years, some dramatic results have been obtained. Some of
the reported successes have occurred in countries or
regions where malaria transmission was already low [3]
but, in other cases, a significant downward trend has been
achieved in places where transmission is stable; Zanzibar
[4], Eritrea [5], The Gambia [6] and Kenya [7,8] are good
examples.
These successes have involved scaling up of existing con-
trol measures, notably treatment with artimisinin-based
combination therapy (ACT) or other effective drug combi-
nations, insecticide-treated nets (ITNs) and, increasingly,
a return to insecticide-residual spraying (IRS). There has
also been increased use of intermittent preventive treat-
ment in pregnancy [9], and this approach to malaria con-
trol is being explored in infants and older children. A high
level of commitment to the discovery of new drugs and
insecticides is essential to ensure that these gains are not
lost when the drugs and insecticides in current use lose
their effectiveness.
Effective malaria control is defined as a reduction in cases
of clinical malaria and mortality to a level at which
malaria ceases to be a major problem. The malaria para-
site still persists in the community, country or region and,
if the control measures are not sustained, there is every
likelihood that transmission and numbers of cases will
increase rapidly again. However, the somewhat surprising
impact of scaling-up the use of existing control measures
has prompted the call, first by the Bill and Melinda Gates
Foundation, quickly endorsed by WHO, and then by the
Roll Back Malaria partnership, for malaria elimination to
become the new goal. This has a very different and far
more challenging aim of stopping transmission com-
pletely within a defined region, so that the only cases of
malaria that occur are through importation from outside
the region [10]. Elimination by this definition can be
achieved only by killing all of the parasites within the tar-
get population.
It is clear that, despite the successes achieved by scaling-up
use of existing tools, additional or alternative strategies
will be needed if malaria elimination is to be achieved – a
possible exception being some island situations [11].
Persistence of infection
The focus of enhanced research and malaria control has,
understandably, been primarily on P. falciparum malaria,
given the mortality and severity of disease associated with
this species. However, there is increasing recognition that
the risk of infection and the burden of disease due to P.
vivax  malaria is substantial and, although of limited
importance in sub-Saharan Africa, this parasite is often
the dominant one in the other major endemic regions of
the world. Frequently, P. vivax and P. falciparum occur
sympatrically and elimination programmes, in such cases,
must take account of the different challenges presented by
the two species, especially in terms of persistence of infec-
tion, and the complex interactions between the species.
This complex balance may be disturbed by vaccination
against either P. falciparum or P. vivax in areas where both
parasites are prevalent. Eliminating P. falciparum but not
P. vivax would be a step forward, but if this was all that
was achieved could damage the reputation of a malaria
elimination programme.
Malaria elimination means stopping infection. This may
be achieved if the measures directed against asexual para-
sites are fully effective, or by targeting sexual stages
directly with drugs or vaccines.
Transmission of P. falciparum
In areas of high transmission, asexual parasite densities
are highest in young children, and it is in this age group
that microscopic detection of gametocytes is most com-
mon. Both asexual blood stage and gametocyte densities
then decline with age, though the patterns of decline are
somewhat different [12]. Epidemiological studies show,
however, that transmission of P. falciparum is as depend-
ent on the parasites not detected by routine blood screen-
ing as on those that are readily seen. The cumulative
evidence for the importance of low-grade asymptomatic
infections as a reservoir for infection of mosquitoes is
strong. In areas of highly seasonal malaria, where there is
often a long dry season in which little or no transmission
occurs, persisting very low gametocytaemias are the
source from which transmission occurs at the onset of the
subsequent rainy season [13]. In areas where the endemic-
ity of malaria allows acquired immunity to develop, there
are many asymptomatic individuals, particularly adults,
who are an important source of infection for mosquitoes
[14,15].
Detection of gametocytes using molecular techniques,
such as reverse transcriptase polymerase chain reaction
(RT-PCR) [13] and quantitative nucleic acid sequence-
based amplification (QT-NASBA) has shown that gameto-Malaria Journal 2008, 7(Suppl 1):S10 http://www.malariajournal.com/content/7/S1/S10
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cytaemias can persist at sub-microscopic levels for months
and that the prevalence of gametocytaemic individuals is
much higher than was assumed from blood film examina-
tions [16]. Of particular relevance to consideration of
malaria elimination, Shekalaghe et al [17], in a study of
parasite prevalence in an area of low, seasonal transmis-
sion in Tanzania, showed that, while microscopically the
parasite rates were low (1.9% asexual parasites, 0.4%
gametocytes), QT-NASBA revealed much higher preva-
lence rates (32.5% asexual parasites and 15.0% gameto-
cytes).
These observations indicate the need to adopt a commu-
nity-based approach to elimination; any selective inter-
ventions used should be based more on the focality of
malaria [18], rather than on particular groups especially at
risk from the clinical consequences of malaria infection,
such as young children or pregnant women. Those at low
risk clinically may still be important transmitters of infec-
tion.
Transmission of P. vivax
A key factor in the persistence of P. vivax is the fundamen-
tal difference in the life cycle shown by P. vivax and Plas-
modium ovale, compared with P-. falciparum and
Plasmodium. malariae, namely the occurrence of dormant
hypnozoites in the liver, from which relapse infections
can emerge, weeks, months or years after infection.
There is some evidence from use of PCR techniques, that,
as for P. falciparum, the number of P. vivax infections in an
affected community is generally significantly underesti-
mated [19]. Though the pattern of gametocyte production
in P. vivax is different from that of P. falciparum, low grade
asymptomatic infections are equally likely to give rise to
infectious gametocytes.
Progress with vaccine development
The challenges set to vaccine developers [20] by those
who drew up the malaria vaccine road map are first, by
2015, to produce a licensed vaccine that has a protective
efficacy of more than 50% against severe disease and
death from malaria which lasts longer than one year. Sec-
ondly, by 2025, to develop a vaccine with a protective effi-
cacy greater than 80% against clinical disease and death
that lasts longer than four years.
These targets focus on the prevention of clinical disease,
especially its severe and life-threatening form, valid objec-
tives for vaccines that are to be introduced into areas of
medium or high transmission. A vaccine that conformed
to the 2015 objective, providing protection to half of
those vaccinated, would be valuable as part of an inte-
grated control programme alongside vector control and
chemo-preventative measures. That level of efficacy would
not justify its use alone as an alternative to other means of
malaria control.
The expanding programme of experimental vaccine-
related research has two broad but overlapping
approaches. One is to achieve a much needed better
understanding of the nature of protective immune mech-
anisms against malaria, thus providing a basis for rational
vaccine design [21]. The other approach is more empirical
and involves issues of design and presentation as vaccines
of antigens that have been recognised for a long time and
which are known to have an important role in the para-
site's life cycle.
Pre-erythrocytic stage vaccines
The primary objective of pre-erythrocytic stage vaccines is
provision of a level of protection that prevents any inva-
sion of the blood and hence any clinical malaria. This has
been achieved readily in experimental malarias by vacci-
nation with radiation-attenuated sporozoites; this formed
the starting point for the extensive investigations into pre-
erythrocytic vaccines. Complete protection was also
achieved in humans against P. falciparum and P. vivax by
exposing them to the bites of mosquitoes that had been
irradiated to attenuate their sporozoites. However, this
delivery procedure was totally impractical and the
research emphasis shifted to the synthetic design and
genetic-engineering of sub-unit vaccines [22].
There has, however, been a renewal of interest in the
development of attenuated-sporozoite vaccines. Given
the high level of sterile protection these whole organism
vaccines can induce, this is a very welcome development.
Stephen Hoffman established and directs Sanaria Inc. spe-
cifically to produce radiation-attenuated sporozoites of P.
falciparum from infected mosquitoes in sufficient quantity
and in a way that meets the regulatory standards required
for their use as a vaccine [23]. This has been achieved and
phase I/2a clinical trials will begin shortly using irradia-
tion-attenuated sporozoites delivered by intradermal or
subcutaneous injection.
Genetic attenuation of sporozoites is also being investi-
gated. Mueller et al [24] produced sporozoites from Plas-
modium berghei deficient in the vis3 gene. These gave
complete protection when used for vaccination. Sporo-
zoites lacking 6-cysteine secretory proteins required for
parasitophorous vacuole formation are equally effective
vaccines [25]. The immune responses of importance fol-
lowing vaccination with attenuated sporozoites are
CD8+T cell-mediated with production of interferon
gamma [26-28].
Synthetic and genetically-engineered sub-unit vaccines
have generally been based on the two surface proteins, cir-Malaria Journal 2008, 7(Suppl 1):S10 http://www.malariajournal.com/content/7/S1/S10
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cumsporozoite protein (CSP) and thrombospondin-
related anonymous protein (TRAP) involved in sporo-
zoite motility and invasion of liver cells. Most of the phase
2 trials of vaccines based on these antigens, using a variety
of vaccine constructs, have given poor results and it is per-
haps surprising that the RTS, S vaccine candidate has
proved to be much more promising. This vaccine is a
hybrid molecule expressed in yeast, that consists of the
tandem repeat tetra-peptide (R) and C-terminal T-cell
epitope containing (T) regions of CSP fused to the hepati-
tis B surface antigen (S), plus unfused S antigen. The adju-
vant ASO2, which consists of an oil in water emulsion
containing immunostimulants monophosphoryl lipid A
and QS-21, a fraction of Quillaia saponaria, is an essential
component of the vaccine. Variants of ASO2 have been
tested successfully [29], and an alternative adjuvant,
ASO1, where a liposomal formulation replaces the oil in
water emulsion, has given very encouraging results
[30,31].
The first challenge trials with RTS, S/ASO2 gave impres-
sive, but short-lived, protection in naïve adults [32]. Sim-
ilarly, in a trial in Gambian adults, there was greater than
70% protection against parasitaemia in the nine weeks
post-vaccination, but the immunity waned rapidly [33].
The most comprehensive study of RTS, S/AS02 has been
in children in Mozambique, who have been followed up
for two years. Over this period, there was 30% protection
against clinical malaria and close to 50% protection
against severe malaria [34]. Most recently, in a small-scale
trial in infants designed primarily to test safety and immu-
nogenicity, RTS, S/AS02D had a vaccine efficacy of 65.9%
against new infections in the six months of follow-up
[35]. A series of phase 2 studies preparatory to a large
phase 3 trial and potential licensure of this vaccine are in
progress.
RTS, S is several years ahead of any other vaccine in terms
of assessment of its efficacy in clinical trials. Trials of other
pre-erythrocytic stage vaccines, based on CSP, TRAP and
other liver stage antigens, several of which have used viral
vector delivery systems, have shown some initial promise,
but are not sufficiently advanced or effective to be consid-
ered yet for evaluation in phase 3 trials [36,37].
Asexual blood-stage candidate vaccines
A range of blood stage antigens have progressed to phase
1 and phase 2 trials. Most are molecules that have been
identified as being involved in the process of invasion of
erythrocytes by merozoites [38]. Promising results from
studies with rodent malarias are proving difficult to trans-
fer to human infections [39-43], though some early
encouraging results with MSP-3 antigen have been
reported [44]. The expectation is that such candidate vac-
cines might give protection against disease, but not
against infection. This was the case with one phase 2 clin-
ical trial of a vaccine containing MSP-1, MSP-2 and RESA
antigens which reduced parasite density, but not preva-
lence of infection [45]. It was also strain-specific in its
effect and the polymorphism of these antigens, coupled
with the variability in invasion pathways P. falciparum can
adopt [46,47] are a severe challenge to the design of this
kind of vaccine. Blocking invasion of reticulocytes by P.
vivax merozoites might be a more hopeful strategy, given
that the Duffy antigen is thought to be the obligatory
receptor on the erythrocyte surface [48] yet, even here an
alternative invasion strategy has been proposed [49].
Plasmodium falciparum-infected erythrocytes express
highly variable parasite molecules on the red blood cell
surface. Naturally-acquired immunity involves variant-
specific responses to these antigens and the very complex-
ity of these responses may limit the potential of these anti-
gens as vaccine candidates. However, this variability
might be exploitable for specifically targeted vaccines. The
P. falciparum-infected erythrocytes that sequester in the
placenta of pregnant women have a very selected sub-set
of variant surface antigens, notably one coded VAR2CSA,
through which they bind to chondroitin sulphate A (CSA)
in the placenta. This opens the possibility of designing a
vaccine that would be beneficial to pregnant women [50],
but which would probably not affect the other variants
that circulate and sequester elsewhere using different
receptor-ligand interactions. Another postulated
approach to vaccination, much less studied, is to block
parasite molecules that mediate disease by inducing pro-
inflammatory responses. Glycosylphosphotidyl-inositol
(GPI) is strongly implicated [51], but any vaccine effect
would alleviate symptoms of disease without affecting
infection. The immunity induced by such a vaccine might
prevent some of the severe complications of malaria
mediated by cytokine-induced response to infection. Use
of vaccines of this kind, however, has the potential disad-
vantage of damping down the early clinical features of
malaria, such as fever, which could delay the time before
a patient sought treatment whilst still allowing parasite
multiplication to occur.
Transmission-blocking vaccines
The concept of a malaria vaccine that could provide an
effective immune response when the antibodies induced
had been ingested by blood-feeding mosquitoes, was
developed thirty years ago [52]. The target antigens of the
passively transferred antibodies that blocked transmission
were shown to be sexual-stage specific surface molecules
(Pfs 48/45 and Pfs 230 in P. falciparum), that are involved
in the process of fertilization of macrogametocytes by
microgametes. Subsequently, other antigens (P25 and
P28 proteins), that are uniquely expressed in the mos-
quito by zygotes and ookinetes (i.e. after fertilization),Malaria Journal 2008, 7(Suppl 1):S10 http://www.malariajournal.com/content/7/S1/S10
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were shown to be equally good for induction of transmis-
sion-blocking immunity (TBI). The end result in each case
is to prevent sporogonic development in the vector.
Experimental studies with animal models have shown
that it is possible to induce a highly effective TBI [22,53].
The most extensive studies have focused on Pfs 48/45, Pfs
230, Pfs 25, Pfs 28 of P. falciparum and orthologues in
other Plasmodium species, but more potential vaccine can-
didates have been identified [54].
The gamete surface molecules (48/45 and 230) are also
expressed in gametocytes circulating in the blood. This
has made it possible to study the nature and duration of
naturally-acquired sexual-stage specific immunity, and
has contributed importantly to an understanding of the
epidemiology of gametocytes in comparison with that of
the much more comprehensively studied asexual blood
stages [12]. The P25 and P28 proteins are not expressed in
gametocytes and hence there is no natural infection-
related immunity to them. However, the mRNA that
encodes these proteins is measurable in gametocytes and
is used as the basis of highly sensitive means of detecting
gametocytes [16].
The transmission-blocking activity of sera from vaccinated
animals or humans, or from individuals naturally
infected, has mostly been assessed by an ex vivo assay, dur-
ing which mosquitoes feed through a membrane on
blood containing gametocytes and a serum under test.
Comparison with controls of the numbers of mosquitoes
that become infected, and the number of oocysts they
carry, gives a measure of the potency of the serum under
test.
Experimentally, sera from rabbits, monkeys and mice vac-
cinated with vaccine candidates Pfs25 from P. falciparum
and Pvs25 from P. vivax contained antibodies with trans-
mission-blocking activity. The antibody levels measured
by ELISA correlated with both oocyst reduction and the
number of mosquitoes that failed to become infected
[55]; antibody levels persisted at a high level for months
after a second or third injection in mice [56]. Phase 1
human vaccine trials were also effective [57], though not
yet at the level that will be required and can be achieved
experimentally.
Alternatives to the membrane-feeding assay are also being
assessed for evaluation of transmission-blocking activity.
Transmission of the transgenic P. berghei expressing the
P25 antigens of either P. falciparum [58] or P. vivax [59]
was blocked by antibodies obtained from animal vaccina-
tion and phase 1 clinical trials.
Though Pfs48/45 has been clearly shown to induce anti-
bodies that prevent fertilization and correlate with trans-
mission-blocking activity, the conformational nature of
the epitopes, and the cysteine-rich nature of the protein
has made production of a correctly folded recombinant
molecule difficult. Encouragingly, production of a stable,
properly folded C terminal portion of the molecule that
induces transmission-blocking antibodies has recently
been described [60,61].
Use of vaccines in an elimination programme
Since elimination of malaria requires complete removal
of all parasites, the focus of measures used to accomplish
this goal is quite different from that for disease control.
Whether the measures used for parasite elimination
involve drugs [9] or vaccines, or a combination of the two,
what is required are tools that prevent production of
gametocytes or that render them non-infective to mosqui-
toes.
The ideal vaccine would be one that induces complete
sterilizing immunity or which is fully effective at blocking
transmission. Nothing approaching induction of a sterile
immunity has been shown so far and it seems unlikely
that this will be achieved with sub-unit vaccines. This does
not rule out the use of such vaccines as part of an inte-
grated approach to malaria-elimination, but they are
unlikely to induce an anti-parasite immunity of sufficient
efficacy to eliminate all parasites. It remains to be seen
whether attenuated sporozoites, which, in small-scale
studies with a demanding and unusable vaccination
regime, did give full protection, will be as effective in the
trials now beginning.
The transmission-blocking vaccines currently being tested
induce good, but certainly not complete, transmission-
blocking immunity. Since the membrane-feeding and the
transgenic rodent malaria assays allow sera from clinical
trials to be tested for efficacy, it is possible to set up a series
of small-scale phase 1/2a trials with different vaccine con-
structs and vaccination regimes. It should then be possible
to make speedy progress towards improving vaccine effi-
cacy and selecting the best vaccine for development. There
is an urgency to do this.
There are biological and clinical features of infection that
need to be taken into account in designing elimination
measures that include vaccines. These are listed in Table 1
and, in particular, involve the interaction between the
acquired immune response and the gametocyte infectious
reservoir. As discussed earlier in this review, the gameto-
cyte reservoir is grossly underestimated when assessed by
conventional means, even in areas of low transmission.
The same is true of asexual parasitaemias. In areas of sta-
ble transmission, numbers of gametocytes decrease withMalaria Journal 2008, 7(Suppl 1):S10 http://www.malariajournal.com/content/7/S1/S10
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age more rapidly than do numbers of asexual parasites,
but the proportion of individuals who are gametocytae-
mic is actually higher at lower transmission intensities
[12]. An increase in gametocyte prevalence has also been
seen following control studies [62]. For this and other rea-
sons adult carriage becomes as important as that of chil-
dren in terms of the source of infection for mosquitoes.
Naturally acquired immune responses to the sexual stages
of the malaria parasite develop rapidly (in individuals
with little or no previous exposure to malaria) and have
transmission-blocking activity [63]. However, in endemic
areas, the ability of sera to reduce transmission decreases
in older age groups, corresponding to a reduction in
gametocyte numbers [64]. The biological significance of
this loss of immunity has been reviewed [12] and further
supports evidence that adults with few parasites are never-
theless important as a reservoir of infection. There is evi-
dence too, particularly for P. vivax, that a low level of
immunity can enhance transmission to mosquitoes [65].
It is frequently stated that, as malaria control and elimina-
tion programmes progress, the population no longer has
any immunity and becomes highly susceptible to epi-
demic infections. While this is true to some extent, espe-
cially for younger age groups, there is another aspect of
immunity to consider. It is well known that those who
had immunity to malaria quite rapidly lose their clinical
immunity if no longer exposed and may develop a symp-
tomatic infection at low parasite densities on subsequent
exposure. However, the anti-parasite immunity they had
acquired can persist for many years [66-68]. In other
words, there is immunological memory directed against
the infection. The relevance of this to malaria elimination
is that, for many years, there may be a proportion of the
population capable of supporting low grade infections
from which gametocytes can be derived.
Conclusion
Elimination programmes are focused on populations, not
individuals, and, optimally, a herd immunity that is sus-
tained and prevents transmission is required. The current
vaccine development programmes are largely concerned
with disease control and must be sustained, but, from the
results obtained so far in clinical trials of the RTS, S vac-
cine, the impact is not dissimilar to that of ITNs, i.e. there
is a greater impact on severe disease than on infection. It
is difficult to imagine partially effective asexual blood
stage vaccines being very useful for parasite elimination.
Given that all age groups can potentially provide a source
of infection to mosquitoes, a high proportion of the pop-
ulation will need to be given a vaccine. However, there is
much evidence to show that malaria is a highly focal dis-
ease and, initially at least, it might be beneficial to vacci-
nate those at greatest risk of being bitten by vector
mosquitoes. Whatever vaccine is employed, pre-erythro-
cytic or transmission-blocking, its efficacy would need to
be very high to achieve elimination [9].
A transmission-blocking vaccine has no direct effect on
clinical malaria, but would break the life-cycle between
human and malaria. It might be used as a stand-alone vac-
cine, but, more appropriately, as part of an integrated pro-
gramme involving drug-treatment and vector control. The
concept of a multi-component, multi-stage vaccine [69]
with an effect from one component mainly on disease and
from another on infection is intuitively appealing though
the type of vaccine design required to kill parasites or
Table 1: Acquired immunity, persistence of gametocytes, and transmission.
1. Acquired immunity to asexual blood stages increases with exposure but allows the persistence of low level parasitaemias from which 
gametocytes develop.
2. Anti-parasitic immunity will persist after interruption of transmission and may allow the occurrence of asymptomatic infections and hence 
gametocytaemias for a number of years.
3. Transmission-blocking immunity to gametocytes develops rapidly then wanes so that adults carrying small numbers of gametocytes are less 
likely to have antibodies that render them non-infective.
4. Low levels of transmission-blocking antibodies have been shown to enhance transmission.
5. The gametocyte reservoir is much larger than that determined by blood film examination even in areas where transmission is low. 
Transmission of infection can occur from individuals with very low numbers of gametocytes.
6. Gametocyte infectivity is broadly related to gametocyte density but small numbers of infectious gametocytes in adults are as important in 
maintaining transmission as larger numbers of gametocytes in children susceptible to clinical attacks of malaria.
7. A vaccine for elimination of malaria must ensure everyone susceptible to malaria infection is protected completely or that all gametocytes are 
made non-infective.Malaria Journal 2008, 7(Suppl 1):S10 http://www.malariajournal.com/content/7/S1/S10
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render gametocytes non-infective to mosquitoes might be
quite different from vaccines whose beneficial effect is
mainly against disease severity. What is needed is an
expanded malaria vaccine programme targeting the par-
ticular requirements of malaria elimination.
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